Portfolio news · Major win
Endurance RP wins landmark China approval for Senstend
A regulatory milestone moves a portfolio holding into commercial-stage status, unlocking milestone payments and a major market.
What happened
Endurance RP secured approval from China's National Medical Products Administration for Senstend, marking its transition into a commercial-stage biopharmaceutical company. Under its partnership with Jiangsu Wanbang Biopharmaceutical, a Fosun Pharma unit, the approval triggers milestone payments, with further commercial milestone and royalty payments tied to sales performance.
The Hong Kong-listed group (formerly Regent Pacific) holds corporate and strategic investments focused on healthcare, wellness and life sciences, and continues to develop interests in longevity technology.
Why it matters for Gorilla Tech Capital
For Gorilla Tech Capital, the approval illustrates the optionality embedded in the legacy portfolio: a long-held position reaching a regulatory inflection point that converts development risk into contracted, commercial cash flows. Outcomes of this kind support distributions to existing limited partners.
Source: Endurance RP announcement (2026)